醫藥股普遍隨大市反彈 艾美(06660.HK)漲逾9% 藥明生物曾彈逾7%
人匯由逾五個月低位止跌回升,人民幣兌美元中間價今天上調199點,報7.0157。恆指繼上周五曾跌至19,352創約兩個月低喘定後,今早高開28點,早段曾低見19,410拒絕再下,在新經濟股及金融股主導,曾重越250天及10天線(19,696及19,743),最多回升334點或1.7%高見19,784(受制20天線19,818),現報19,698,僅回升247點或近1.3%,總成交額502億元。
醫藥板塊今天普遍隨大市反彈,尤其是艾美疫苗(06660.HK)扭三連跌,股價高見53.5元,現報51.6元,回升9.4%。
藍籌藥明生物(02269.HK)扭三連跌,股價由逾半年低位曾反彈7.4%至45.25元遇阻,現報44.2元,回升4.9%,未能企穩10天線(45.07元);藥明康德(02359.HK)曾重越10天及20天線(69.7元及70.1元),最高見70.65元,現報69.6元,續彈1.5%。
藍籌中生製藥(01177.HK)、石藥(01093.HK)及翰森(03692.HK)升逾1.5%-3%,後者跑贏曾高見13.02元(暫受制10天線13.08元)。
三葉草生物-B(02197.HK)及開拓藥業-B(09939.HK)扭三連跌,股價回升逾2%,後者股價曾由上市低位回升逾4%高見4.33元,現報4.25元,僅回升2.4%。
信達生物(01801.HK)、白雲山(00874.HK)、神威藥業(02877.HK)、四環醫藥(00460.HK)及百濟神州(06160.HK)彈逾1%-3%,後者最強報141.4元。
國家醫療保障局副局長施子海上周尾於發布會上表示,長期以來,內地藥品和高值醫用耗材價格存在虛高現象,特別是一些「進口老藥」,儘管已經過專利期,但仍以較高的價格內地銷售,高值醫用耗材價格更是遠高於國際水平。針對該狀況,當局將會同有關部門積極推進藥品、高值醫用耗材集採,通過降低中選企業的生產和營銷成本,實現中選產品降價。下一步,將持續推進醫藥集中帶量採購的擴面提質,堅持國家和地方上下聯動、一體推進。在國家層面上,今年已開展第八批藥品集採,還將開展第四批高值醫用耗材的集採,主要是針對眼科的人工晶體和骨科的運動醫學類耗材,適時還將開展新批次的藥品集採。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.